[Frontiers in Bioscience 5, d367-371, March 1, 2000]

HOME
Current Issue
VITAL LINKS
INDEX
PDF FILE
ACCESS PUBMED
REPRINTS
CAVEAT LECTOR

Send correspondence to:

Andrew Arnold, M.D.,
Center for Molecular Medicine,
University of Connecticut Health Center,
263 Farmington Avenue,
Farmington, CT 06030-3101

Tel:860-679-7640,
Fax: 860-679-7639,
E-mail: AArnold@nso2.uchc.edu3

KEY WORDS

Parathyroid, Adenoma, Cyclins, Neoplasms, Cancer, Tumor, Growth, Proliferation, Review

SEARCH FBS

Copyright © Frontiers in Bioscience, 1995

CYCLIN D1 IN PARATHYROID DISEASE

Sanjay M. Mallya and Andrew Arnold

Center for Molecular Medicine, University of Connecticut Health Center, Farmington, CT. USA

TABLE OF CONTENTS

1. Abstract
2. Introduction
3. Cloning of the PRAD1/Cyclin D1 oncogene
4. Cyclin D1 in parathyroid tumorigenesis
5. Future Directions
6. References

1. ABSTRACT

Primary hyperparathyroidism (HPT), most commonly due to parathyroid adenoma, is a disorder characterized by excessive secretion of PTH. So far, abnormalities in two genes, cyclin D1 and MEN1, have been implicated in the development of parathyroid adenomas. Cyclin D1, now an established Oncogene involved in numerous human cancers, was first identified and recognized as an Oncogene in the study of parathyroid tumors. A subset of parathyroid adenomas contains a clonal rearrangement that places the PTH gene's regulatory sequences in proximity to the cyclin D1 Oncogene causing its overexpression, and 20-40% of parathyroid adenomas overexpress the cyclin D1 protein. Transgenic animal models have further confirmed the role of cyclin D1 as a driver of abnormal parathyroid cell proliferation. Future studies on the mechanism of cyclin D1's oncogenicity and its interactions with other parathyroid growth regulators will further our understanding of parathyroid cell biology and may prove useful clinically.

2. INTRODUCTION

The parathyroid glands are endocrine organs that regulate calcium homeostasis. The major target organs of parathyroid hormone (PTH) are the bone and kidney. PTH increases bone resorption to mobilize calcium into the circulation. In the kidney, PTH enhances calcium reabsorption and decreases reabsorption of phosphate. PTH also stimulates renal production of 1,25-dihydroxyvitamin D3 [1,25 (OH)2 D3], which in turn enhances intestinal absorption of calcium. Thus, the physiological effects of PTH increase the concentration of calcium in the circulation. Negative feedback from calcium and 1,25 (OH)2 D3 modulate parathyroid function. Hypocalcemia causes increased PTH secretion and proliferation of parathyroid cells. These effects are mediated, at least in part, via the calcium-sensing receptor (CaR) expressed on the parathyroid cell surface. Similarly, 1,25 (OH)2 D3, acting through its nuclear receptor, suppresses the synthesis of PTH and parathyroid cell proliferation. Thus, PTH secretion is tightly coupled to the parathyroid cell's ambient calcium level. States of abnormal parathyroid cell proliferation are typically associated with dysregulation of PTH secretion.

Primary HPT is a relatively common endocrine disorder with an incidence of approximately 1 per 1000 (1). It is characterized by hypersecretion of parathyroid hormone (PTH) and resultant hypercalcemia. Most cases of primary HPT (about 85%) result from a solitary adenoma in one of the parathyroid glands. Multi-gland hyperplasia is found in about 15% of primary HPT patients. Primary hyperplasia may occur sporadically or may be part of a familial HPT syndrome such as Multiple Endocrine Neoplasia (MEN) type 1 or 2A. HPT is also part of other inherited syndromes, such as the hereditary hyperparathyroidism jaw tumor syndrome (HPT-JT), familial isolated hyperparathyroidism (FIHP) and familial hypocalciuric hypercalcemia (FHH). Very rarely, in less than 1% of patients, primary HPT is a consequence of parathyroid carcinoma.

Secondary HPT is an increase in PTH secretion as a physiological response to hypocalcemic states, for example in end stage renal disease or vitamin D-deficiency. Long-standing secondary HPT may lead to autonomous PTH secretion, a state where the parathyroid glands have ceased to respond appropriately to physiological regulation. This is referred to as refractory secondary HPT or tertiary HPT.

3. CLONING OF THE PRAD1/CYCLIN D1 ONCOGENE

The underlying molecular genetic pathology of parathyroid adenomas is only partially understood. The first clue to the nature of these lesions was provided by examinations of their clonality (2). These studies showed that parathyroid adenomas are monoclonal neoplasms, suggesting that these tumors are caused by mutations that alter the growth regulation of parathyroid cells. Other early molecular analyses revealed the presence of tumor-specific DNA rearrangements in a subset of adenomas--in such rearrangements the 5' PTH gene regulatory region becomes separated from its coding exons and was shown to recombine with a novel DNA locus, D11S287 (3). This rearrangement bore similarities to specific chromosomal translocations that occur in various B-cell lymphomas, wherein the tissue-specific regulatory sequences of the immunoglobulin heavy chain gene are juxtaposed with oncogenes like BCL-2 or C-MYC, causing their overexpression in the B-lineage cells. Thus, by analogy, it was expected that DNA from the non-PTH side of the breakpoint in the parathyroid tumors must harbor an Oncogene that provides the host parathyroid cell with a selective growth advantage. An mRNA transcript from this breakpoint-adjacent gene was identified and was found to be dramatically overexpressed in these parathyroid adenomas (4), suggesting that the tissue-specific enhancer elements of the PTH gene were indeed deregulating the expression of this putative oncogene. Subsequent cloning of this candidate Oncogene led to the identification of a novel gene (PRAD1/Cyclin D1) with sequence similarities to cyclins (5). The PTH gene is localized to chromosomal region 11p15, whereas the cyclin D1 Oncogene maps to 11q13 (3). Thus, the simplest explanation for this rearrangement is a pericentromeric inversion, inv(11)(p15;q13), that positions the 5' PTH regulatory region upstream of the cyclin D1 gene (Figure 1). To date, cyclin D1 is the only established parathyroid tumor oncogene.

Figure 1. Schematic diagram of the pericentromeric inversion of chromosome 11. The rearrangement places the 5' PTH regulatory region upstream of the cyclin D1 gene.

Cyclin D1 was also cloned as a murine gene induced by growth factor exposure in a macrophage cell line (6) and as a cDNA capable of rescuing yeast made mutant in their G1-phase cyclins (7). The cyclin D1 gene encodes a 35 kDa protein that shares structural homology and some functional properties with other cyclins (5, 7, 8). The cyclin D1 protein contains a retinoblastoma (pRB)-binding domain (9) as well as the conserved 'cyclin boxes'. Cyclin D1 complexes with and activates its kinase partners cdk4 and cdk6 in the G1 phase of the cell cycle. The activated kinases participate in the phosphorylation and inactivation of pRb, effecting entry into S-phase (Figure 2). Thus, inactivation of the tumor suppressive effects of pRb is one plausible mechanism for the oncogenic activity of cyclin D1. The cyclin D1 gene is amplified in several human malignancies, including breast cancers (10-12) and head and neck carcinomas (13). Moreover, activating mutations of CDK4 have been detected in human melanomas (14) and CDK4 is amplified in sarcomas and gliomas (15, 16). Also, the cdk4-inhibitor p16 has been well established as a tumor suppressor. Thus, the cyclin D1 pathway is a central target in oncogenesis.

Figure 2. Schematic representation of oncogenicity of cyclin D1 in parathyroid tumor cells. Based on the known function of cyclin D1 in cell-cycle regulation, cyclin D1 may possibly bind to cdk4 or cdk6, which phosphorylate pRb. Phosphorylated pRb dissociates from transcription factors in the E2F family, permitting transcription of genes involved in transition of the cell from G1 to S phase. Alternatively, other, non-cdk-dependent mechanisms may also be operational in these tumor cells.

4. CYCLIN D1 IN PARATHYROID TUMORIGENESIS

As noted above, a subset of parathyroid adenomas contain clonal rearrangements that juxtapose the PTH 5' regulatory region with the cyclin D1 gene. The 11q13 chromosomal breakpoint may be close to cyclin D1 or may extend to as much as 300 kb centromeric of cyclin D1 (Y. Hosokawa et al, unpublished data). This variability in the location of the breakpoint complicates standard approaches for detection of the rearrangement. Thus, there are no accurate estimates of the percentage of parathyroid adenomas that harbor such cyclin D1-activating rearrangements. However, as determined by immunohistochemistry, 20-40% of parathyroid adenomas overexpress cyclin D1 (17-19). In addition to the described chromosomal rearrangement, other molecular mechanisms for cyclin D1 overexpression such as gene amplification, rearrangement with other parathyroid-specific promoters or transcriptional activation may also be operational in these tumors.

In addition to the clonality of cyclin D1 gene lesions, animal models have provided further evidence that cyclin D1 overexpression is indeed capable of driving parathyroid tumorigenesis. Our laboratory has generated a transgenic mouse model for parathyroid neoplasia. These mice harbor a transgene in which the cyclin D1 gene is placed under the control of the PTH regulatory region, thereby mimicking the rearrangement and resultant cyclin D1 overexpression observed in the human tumors. By the age of 6-10 months, these mice develop HPT, as evidenced by parathyroid enlargement and increased serum calcium and PTH levels (20). Thus, tissue-specific overexpression of cyclin D1 does induce parathyroid cell proliferation resulting in HPT.

Primary HPT is also a component of the inherited Multiple Endocrine Neoplasia syndromes, especially MEN-1. The MEN1 gene was recently identified (21) and maps to chromosome 11q13, a region of frequent allelic loss in sporadic parathyroid tumors (22-26). Indeed, acquired inactivation of both alleles of the MEN1 gene has been shown to contribute to 12-16% of parathyroid adenomas (27-29). The function of menin, the protein product of the MEN1 gene, remains to be fully elucidated although evidence supports a role in transcriptional control (30). It was recently reported that sporadic adenomas with MEN1 mutations have a marginally higher frequency of allelic losses and chromosomal imbalances compared with sporadic adenomas without involvement of the MEN1 gene. Although these differences were not statistically significant, they suggest a possible role for MEN1 in maintenance of chromosomal stability (31). Involvement of cyclin D1 in the pathogenesis of MEN 1-related tumors is unknown. It will be important to determine if there is cooperation between cyclin D1 and menin in the development of sporadic- and MEN1-related parathyroid neoplasia.

True malignancy involving the parathyroid is rare, especially so considering the common occurrence of benign parathyroid neoplasia. Differences in the regions of frequent chromosomal gains and losses between adenomas and carcinomas (26, 32, 33) suggest that the pathogenesis of these two lesions are different and that adenomas are not likely to be the precursors of the malignant neoplasm in this tissue. Immunohistochemical studies have detected overexpression of cyclin D1 in 50-91% of parathyroid carcinomas (17, 18), apparently even higher than that observed with parathyroid adenomas. The genetic basis for, and effect of, cyclin D1 activation in the context of parathyroid malignancy remains to be determined.

The molecular basis of severe secondary or tertiary HPT is poorly understood. Because of multigland involvement, it was assumed that this condition predominantly involves polyclonal (non-neoplastic) cellular proliferations. Although this is likely to be the case in the initial proliferative phase, it is now clear that monoclonal parathyroid expansion does occur in most patients with severe secondary or tertiary HPT (34, 35). However, immunohistochemical studies have not detected overexpression of cyclin D1 in parathyroid glands from patients with uremic HPT (19), suggesting an infrequent role for cyclin D1 in the development of this disease. Interestingly, acquired inactivation of the MEN1 gene, also relatively common in sporadic primary HPT, seems to play only a minor role in the clonal expansion of these lesions (35, 36). Thus, the molecular genetic basis for the development of this clonal disease may differ from primary HPT.

5. FUTURE DIRECTIONS

To date, several other frequent genetic abnormalities have been reported in parathyroid adenomas, including loss of chromosomal regions on 1p, 1q, 6q, 9p, 11p, 11q, 13q and 15q and gain of chromosomes 16p and 19p (25, 26, 31, 32, 37, 38). However, genes located in these regions that contribute to neoplastic changes in the parathyroid gland remain to be identified.

Other than the still unproven possibility that pRb may be the tumor suppressor target of 13q deletions in parathyroid carcinomas (39), molecular analyses have failed to detect parathyroid tumor mutations in any of the other genes involved in the cyclin D1 pathway. Specifically, inactivating mutations or homozygous deletions of the p16 and p15 genes occur uncommonly, if ever, in parathyroid adenomas (38). These observations, plus other data suggesting that existing paradigms for cyclin D1 action in tumorigenesis may be too simplistic (40-42), raise the possibility that cyclin D1 may regulate parathyroid-cell growth via yet unknown mechanisms.

Finally, it should be emphasized that a hallmark of parathyroid adenomas is their loss of calcium sensitivity--an apparent resetting of the 'setpoint' mechanism that normally tightly couples PTH secretion with ambient calcium levels. However, mutations of the Ca++-sensing receptor gene have not been found in sporadic parathyroid adenomas (43). Further it is clear that primary deregulation of cyclin D1 can cause a secondary disturbance in the calcium-PTH secretory relationship (20, Imanishi et al, unpublished data). Examination of the contribution of cyclin D1 overexpression and other tumorigenic changes to deregulation of setpoint control will elucidate the critical links between proliferation and functional abnormalities in parathyroid neoplasia.

6. REFERENCES

1. Melton, L. J.: Epidemiology of primary hyperparathyroidism. J Bone Miner Res 6, S25-30; (1991)

2. Arnold, A., C. E. Staunton, H. G. Kim, R. D. Gaz and H. M. Kronenberg: Monoclonality and abnormal parathyroid hormone genes in parathyroid adenomas. N Engl J Med 318, 658-662 (1988)

3. Arnold, A., H. G. Kim, R. D. Gaz, R. L. Eddy, Y. Fukushima, M. G. Byers, T. B. Shows and H. M. Kronenberg: Molecular cloning and chromosomal mapping of DNA rearranged with the parathyroid hormone gene in a parathyroid adenoma. J Clin Invest 83, 2034-2040 (1989)

4. Rosenberg, C. L., H. G. Kim, T. B. Shows, H. M. Kronenberg and A. Arnold: Rearrangement and overexpression of D11S287E, a candidate Oncogene on chromosome 11q13 in benign parathyroid tumors. Oncogene 6, 449-453 (1991)

5. Motokura, T., T. Bloom, H. G. Kim, H. Juppner, J. V. Ruderman, H. M. Kronenberg and A. Arnold: A novel cyclin encoded by a bcl1-linked candidate oncogene. Nature 350, 512-515 (1991)

6. Matsushime, H., M. F. Roussel, R. A. Ashmun and C. J. Sherr: Colony-stimulating factor 1 regulates novel cyclins during the G1 phase of the cell cycle. Cell 65, 701-713 (1991)

7. Xiong, Y., T. Connolly, B. Futcher and D. Beach: Human D-type cyclin. Cell 65, 691-699 (1991)

8. Lew, D. J., V. Dulic and S. I. Reed: Isolation of three novel human cyclins by rescue of G1 cyclin (Cln) function in yeast. Cell 66, 1197-1206 (1991)

9. Dowdy, S. F., P. W. Hinds, K. Louie, S. I. Reed, A. Arnold and R. A. Weinberg: Physical interaction of the retinoblastoma protein with human D cyclins. Cell 73, 499-511 (1993)

10. Lammie, G. A., V. Fantl, R. Smith, E. Schuuring, S. Brookes, R. Michalides, C. Dickson, A. Arnold and G. Peters: D11S287, a putative Oncogene on chromosome 11q13, is amplified and expressed in squamous cell and mammary carcinomas and linked to BCL-1. Oncogene 6, 439-444 (1991)

11. Arnold, A.: The cyclin D1/PRAD1 Oncogene in human neoplasia. J Invest Med 43, 543-549 (1995)

12. Peters, G., V. Fantl, R. Smith, S. Brookes and C. Dickson: Chromosome 11q13 markers and D-type cyclins in breast cancer. Breast Cancer Res Treat 33, 125-135 (1995)

13. Izzo, J. G., V. A. Papadimitrakopoulou, X. Q. Li, H. Ibarguen, J. S. Lee, J. Y. Ro, A. El-Naggar, W. K. Hong and W. N. Hittelman: Dysregulated cyclin D1 expression early in head and neck tumorigenesis: in vivo evidence for an association with subsequent gene amplification. Oncogene 17, 2313-2322 (1998)

14. Wolfel, T., M. Hauer, J. Schneider, M. Serrano, C. Wolfel, E. Klehmann-Hieb, E. De Plaen, T. Hankeln, K. H. Meyer zum Buschenfelde and D. Beach: A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 269, 1281-1284 (1995)

15. He, J., J. R. Allen, V. P. Collins, M. J. Allalunis-Turner, R. Godbout, R. S. Day, 3rd and C. D. James: CDK4 amplification is an alternative mechanism to p16 gene homozygous deletion in glioma cell lines. Cancer Res 54, 5804-5807 (1994)

16. Khatib, Z. A., H. Matsushime, M. Valentine, D. N. Shapiro, C. J. Sherr and A. T. Look: Coamplification of the CDK4 gene with MDM2 and GLI in human sarcomas. Cancer Res 53, 5535-5541 (1993)

17. Hsi, E. D., L. R. Zukerberg, W. I. Yang and A. Arnold: Cyclin D1/PRAD1 expression in parathyroid adenomas: an immunohistochemical study. J Clin Endocrinol Metab 81, 1736-1739 (1996)

18. Vasef, M. A., R. K. Brynes, M. Sturm, C. Bromley and R. A. Robinson: Expression of cyclin D1 in parathyroid carcinomas, adenomas, and hyperplasias: a paraffin immunohistochemical study. Mod Pathol 12, 412-416 (1999)

19. Tominaga, Y., T. Tsuzuki, K. Uchida, T. Haba, S. Otsuka, T. Ichimori, K. Yamada, M. Numano, Y. Tanaka and H. Takagi: Expression of PRAD1/cyclin D1, retinoblastoma gene products, and Ki67 in parathyroid hyperplasia caused by chronic renal failure versus primary adenoma. Kidney Intl 55, 1375-1383 (1999)

20. Hosokawa, Y., K. Yoshimoto, R. Bronson, T. Wang, E. V. Schmidt and A. Arnold: Chronic hyperparathyroidism in transgenic mice with parathyroid-targeted overexpression of Cyclin D1/PRAD1. J Bone Miner Res 12 (Suppl. 1), S110 (1997)

21. Chandrasekharappa, S. C., S. C. Guru, P. Manickam, S. E. Olufemi, F. S. Collins, M. R. Emmert-Buck, L. V. Debelenko, Z. Zhuang, I. A. Lubensky, L. A. Liotta, J. S. Crabtree, Y. Wang, B. A. Roe, J. Weisemann, M. S. Boguski, S. K. Agarwal, M. B. Kester, Y. S. Kim, C. Heppner, Q. Dong, A. M. Spiegel, A. L. Burns and S. J. Marx: Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 276, 404-407 (1997)

22. Arnold, A. and H. G. Kim: Clonal loss of one chromosome 11 in a parathyroid adenoma. J Clin Endocrinol Metab 69, 496-499 (1989)

23.Friedman, E., K. Sakaguchi, A. E. Bale, A. Falchetti, E. Streeten, M. B. Zimering, L. S. Weinstein, W. O. McBride, Y. Nakamura, M. L. Brandi and et al.: Clonality of parathyroid tumors in familial multiple endocrine neoplasia type 1. N Engl J Med 321, 213-218 (1989)

24. Friedman, E., L. De Marco, P. V. Gejman, J. A. Norton, A. E. Bale, G. D. Aurbach, A. M. Spiegel and S. J. Marx: Allelic loss from chromosome 11 in parathyroid tumors. Cancer Res 52, 6804-6809 (1992)

25. Tahara, H., A. P. Smith, R. D. Gas, V. L. Cryns and A. Arnold: Genomic localization of novel candidate tumor suppressor gene loci in human parathyroid adenomas. Cancer Res 56, 599-605 (1996)

26. Palanisamy, N., Y. Imanishi, P. H. Rao, H. Tahara, R. S. Chaganti and A. Arnold: Novel chromosomal abnormalities identified by comparative genomic hybridization in parathyroid adenomas. J Clin Endocrinol Metab 83, 1766-1770 (1998)

27. Heppner, C., M. B. Kester, S. K. Agarwal, L. V. Debelenko, M. R. Emmert-Buck, S. C. Guru, P. Manickam, S. E. Olufemi, M. C. Skarulis, J. L. Doppman, R. H. Alexander, Y. S. Kim, S. K. Saggar, I. A. Lubensky, Z. Zhuang, L. A. Liotta, S. C. Chandrasekharappa, F. S. Collins, A. M. Spiegel, A. L. Burns and S. J. Marx: Somatic mutation of the MEN1 gene in parathyroid tumours. Nat Genet 16, 375-378 (1997)

28. Farnebo, F., B. T. Teh, S. Kytola, A. Svensson, C. Phelan, K. Sandelin, N. W. Thompson, A. Hoog, G. Weber, L. O. Farnebo and C. Larsson: Alterations of the MEN1 gene in sporadic parathyroid tumors. J Clin Endocrinol Metab 83, 2627-2630 (1998)

29. Carling, T., P. Correa, O. Hessman, J. Hedberg, B. Skogseid, D. Lindberg, J. Rastad, G. Westin and G. Akerstrom: Parathyroid MEN1 gene mutations in relation to clinical characteristics of nonfamilial primary hyperparathyroidism. J Clin Endocrinol Metab 83, 2960-2963 (1998)

30. Agarwal, S. K., S. C. Guru, C. Heppner, M. R. Erdos, R. M. Collins, S. Y. Park, S. Saggar, S. C. Chandrasekharappa, F. S. Collins, A. M. Spiegel, S. J. Marx and A. L. Burns: Menin interacts with the AP1 transcription factor JunD and represses JunD-activated transcription. Cell 96, 143-152 (1999)

31. Farnebo, F., S. Kytola, B. T. Teh, T. Dwight, F. K. Wong, A. Hoog, M. Elvius, W. S. Wassif, N. W. Thompson, L. O. Farnebo, K. Sandelin and C. Larsson: Alternative genetic pathways in parathyroid tumorigenesis. J Clin Endocrinol Metab 84, 3775-3780 (1999) 32. Agarwal, S. K., E. Schrock, M. B. Kester, A. L. Burns, C. S. Heffess, T. Ried and S. J. Marx: Comparative genomic hybridization analysis of human parathyroid tumors. Cancer Genet Cytogenet 106, 30-36 (1998)

33. Imanishi, Y., N. Palanisamy, H. Tahara, A. Vickery, V. L. Cryns, R. D. Gaz, D. Shoback, O. Clark, J. Monchik, M. Wierman, A. Hollenberg, K. Tojo, R. S. K. Chaganti and A. Arnold: Molecular pathogenetic analysis of parathyroid carcinoma. J Bone Miner Res 14 (Suppl 1), S421 (1999)

34. Arnold, A., M. F. Brown, P. Urena, R. D. Gaz, E. Sarfati and T. B. Drueke: Monoclonality of parathyroid tumors in chronic renal failure and in primary parathyroid hyperplasia. J Clin Invest 95, 2047-2053 (1995)

35. Shan, L., Y. Nakamura, M. Murakami, M. Nakamura, A. Naito, K. Kawahara, H. Utsunomiya, I. Mori and K. Kakudo: Clonal emergence in uremic parathyroid hyperplasia is not related to MEN1 gene abnormality. Jpn J Cancer Res 90, 965-969 (1999)

36. Imanishi, Y., H. Tahara, I. Salusky, W. Goodman, M. L. Brandi, T. B. Drueke, E. Sarfati, P. Urena and A. Arnold: MEN1 gene mutations in refractory hyperparathyroidism of uremia. J Bone Miner Res 14 (Suppl 1), S446 (1999)

37. Cryns, V. L., S. M. Yi, H. Tahara, R. D. Gaz and A. Arnold: Frequent loss of chromosome arm 1p DNA in parathyroid adenomas. Genes Chromosomes Cancer 13, 9-17 (1995)

38. Tahara, H., A. P. Smith, R. D. Gaz and A. Arnold: Loss of chromosome arm 9p DNA and analysis of the p16 and p15 cyclin- dependent kinase inhibitor genes in human parathyroid adenomas. J Clin Endocrinol Metab 81, 3663-3667 (1996)

39. Cryns, V. L., A. Thor, H. J. Xu, S. X. Hu, M. E. Wierman, A. L. Vickery, Jr., W. F. Benedict and A. Arnold: Loss of the retinoblastoma tumor-suppressor gene in parathyroid carcinoma. N Engl J Med 330, 757-761 (1994)

40. Zwijsen, R. M., E. Wientjens, R. Klompmaker, J. van der Sman, R. Bernards and R. J. Michalides: CDK-independent activation of estrogen receptor by cyclin D1. Cell 88, 405-415 (1997)

41.Neuman, E., M. H. Ladha, N. Lin, T. M. Upton, S. J. Miller, J. DiRenzo, R. G. Pestell, P. W. Hinds, S. F. Dowdy, M. Brown and M. E. Ewen: Cyclin D1 stimulation of estrogen receptor transcriptional activity independent of cdk4. Mol Cell Biol 17, 5338-5347 (1997)

42. Jacks, T. and R. A. Weinberg: The expanding role of cell cycle regulators. Science 280, 1035-1036 (1998)

43. Hosokawa, Y., M. R. Pollak, E. M. Brown and A. Arnold: Mutational analysis of the extracellular Ca(2+)-sensing receptor gene in human parathyroid tumors. J Clin Endocrinol Metab 80, 3107-3110 (1995)